Parexel International PRXL
-
New Morningstar Analyst Report - Parexel International Corporation
A slowdown in drug-development spending has led to industrywide capacity underutilization, making growth opportunities scarce, and prompting Parexel to restructure its workforce.Parexel may need to price contracts lower than its larger competitors in order to win new business. Any decline in
-
Parexel's Bookings Skyrocket in 3Q; Increased Hiring to Support Demand to Weigh on Near-Term Profits
Parexel PRXL reported a very strong third quarter of its fiscal year 2012 that witnessed solid top- and bottom-line growth on both a year …
-
PAREXEL International ( PRXL ): FQ3 EPS of $0.33 beats by $0.02. Revenue of $356M (+18.1% Y/Y) beats by $6M. Shares -7% AH. (PR)
PAREXEL International ( PRXL ): FQ3 EPS of $0.33 beats by $0.02 . Revenue of $356M (+18.1% Y/Y) beats by $6M . Shares -7% AH. ( PR ) Post your comment!
-
Merck's Transition Will Make It A More Profitable Company
By Jacob Steinberg : Merck ( MRK ) is another pharmaceutical company with a growth challenge as it has to innovate at a rapid rate in order to grow. The company's CEO, Ken Frazier is very committed to keep Merck as one of the strongest players in the industry. The company is currently going through
-
16 Rallying Healthcare Stocks Being Sold By Hedge Funds
By Kapitall : Smart money buying trends can be very interesting to follow, especially when they seem to disagree with recent market behavior. If a stock is rallying but institutional managers are selling the name, for instance, it might indicate you should give it a closer look. We ran a screen on
-
Parexel's Recovery Gains Momentum in Firm's Second Fiscal Quarter of 2012
In the second quarter of its fiscal year 2012, Parexel PRXL continued to see sequential expansion on both a top- and bottom-line basis. We think these improving results signal that the …
-
More on Parexel's FQ2: Though results were only in-line, the company is guiding for FQ3 revenue of $350M-$358M ($334.2M consensus) and EPS of $0.30-$0.32 ($0.23 consensus). In addition, it's guiding ...
… 0.23 consensus). In addition, it's guiding for FY12 (ends in June) revenue of $1.36B-$1.375B ($1.36B consensus) and EPS of $1.09-$1.17 ($1.11 consensus). PRXL now +10% AH. ( PR ) Post your comment!
-
PAREXEL International ( PRXL ): FQ2 EPS of $0.23 in-line. Revenue of $333.2M (+9.5% Y/Y) in-line. Shares +0.7% AH. (PR)
PAREXEL International ( PRXL ): FQ2 EPS of $0.23 in-line. Revenue of $333.2M (+9.5% Y/Y) in-line. Shares +0.7% AH. ( PR ) Post your comment!
-
Contract Research Organizations Still On Sale As Industry Rebounds
By Morningstar : By Lauren Migliore We think the contract research organization (CRO) industry is on the rebound, as evidenced by a resurgence in new business activity and revenue growth during the last year. Widespread top-line growth that began in the second quarter continued into the third; on
-
CROs Will Return to Relevance in 2012
… substantial new costs without an immediate increase in compensating revenue, have weighed on earnings for ICON ICLR and Parexel PRXL --which were named the two strategic partners of Pfizer PFE in May. Although price concessions accompany the substantial volume …